Publication:
Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease

Simple item page
dc.contributor.authorÇELİKEL, ÇİĞDEM
dc.contributor.authorsYilmaz, Yusuf; Eren, Fatih; Yonal, Oya; Kurt, Ramazan; Aktas, Bilge; Celikel, Cigdem Ataizi; Ozdogan, Osman; Imeryuz, Nese; Kalayci, Cem; Avsar, Erol
dc.date.accessioned2022-03-12T17:47:27Z
dc.date.available2022-03-12T17:47:27Z
dc.date.issued2010
dc.description.abstractP>Background The fibroblast growth factor 21 (FGF21) hormonal pathway is a metabolic signalling cascade and has been recently identified as the master hormonal regulator of glucose, lipids and overall energy balance. In this observational, case-control study, we assayed serum levels of FGF21 in patients with nonalcoholic fatty liver disease (NAFLD), a hepatic manifestation of the metabolic syndrome, and examined their association with clinical, biochemical and histological phenotypes. Materials and methods Serum levels of FGF21 were assayed by ELISA in 82 patients with biopsy-proven NAFLD and 77 controls. We analysed associations between FGF21 and the characteristics of patients with NAFLD by multiple linear regression analysis. Results Levels of FGF21 were significantly higher in patients with NAFLD (median 200 pg mL-1; interquartile range: 87-410 pg mL-1) than in healthy controls (median 93 pg mL-1; interquartile range: 70-180 pg mL-1, Mann-Whitney U-test, P < 0 center dot 001). There was a stepwise increase in serum FGF21 levels according to the liver steatosis score (median level in subjects with score 1: 170 pg mL-1; score 2: 220 pg mL-1; score 3: 280 pg mL-1, P for trend < 0 center dot 01). After stepwise linear regression analysis, serum FGF21 levels were the only independent predictor of hepatic steatosis scores in patients with NAFLD (beta = 0 center dot 26; t = 2 center dot 659, P < 0 center dot 01). Conclusions Serum FGF21 levels are increased in patients with NAFLD regardless of potential confounders and represent an independent predictor of liver steatosis. These findings support further investigation of this molecule in metabolic liver diseases.
dc.identifier.doi10.1111/j.1365-2362.2010.02338.x
dc.identifier.issn0014-2972
dc.identifier.pubmed20624171
dc.identifier.urihttps://hdl.handle.net/11424/229759
dc.identifier.wosWOS:000281709800004
dc.language.isoeng
dc.publisherWILEY-BLACKWELL
dc.relation.ispartofEUROPEAN JOURNAL OF CLINICAL INVESTIGATION
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectFibroblast growth factor 21
dc.subjectnonalcoholic fatty liver disease
dc.subjectsteatosis
dc.subjectTYPE-2 DIABETIC-PATIENTS
dc.subjectGROWTH-FACTOR 21
dc.subjectINSULIN-RESISTANCE
dc.subjectMETABOLIC SYNDROME
dc.subjectPLASMA-LEVELS
dc.subjectPPAR-ALPHA
dc.subjectOBESITY
dc.subjectFIBROBLAST-GROWTH-FACTOR-21
dc.subjectSTEATOHEPATITIS
dc.subjectSENSITIVITY
dc.titleIncreased serum FGF21 levels in patients with nonalcoholic fatty liver disease
dc.typearticle
dspace.entity.typePublication
local.avesis.idc7626940-ba7f-4896-afc3-7017cc8e3592
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages6
oaire.citation.endPage892
oaire.citation.issue10
oaire.citation.startPage887
oaire.citation.titleEUROPEAN JOURNAL OF CLINICAL INVESTIGATION
oaire.citation.volume40
relation.isAuthorOfPublicationbc2327ed-471c-42da-86dd-cef77979cda2
relation.isAuthorOfPublication.latestForDiscoverybc2327ed-471c-42da-86dd-cef77979cda2

Files

Collections

Research Outputs